SCREENING AND ENROLLMENT CONSIDERATIONS MTN-038 STUDY-SPECIFIC TRAINING

Similar documents
Section 5. Study Procedures

Section 5. Study Procedures

Overview of Enrollment/Initiate Period 1 Visit Procedures

VOICE Screening Part 1 Visit. Operational Walkthrough Johannesburg, South Africa November 2008

MTN-038 Laboratory Training. May Beamer, Michele Austin MTN Laboratory Center Magee-Womens Research Institute Pittsburgh, PA

Section 5. Study Procedures

MTN 003 MONTHS 1 & 2 VISIT PRESENTATION ZIMBABWE TEAM JULIET MOYO RESEARCH NURSE MARTHA MASAWI COUNSELLOR

Follow-up Visit Procedures MTN-009

Section 6. Participant Follow-up

Section 6. Participant Follow-up

Section 11. Counseling Procedures

Section 6. Participant Follow-up

MTN 015 SPECIMEN REVIEW. Gabriel Banda Core Lab Supervisor UNC Project, Lilongwe

MTN-038 Clinical Considerations. Site Specific Training 11 Sept 2018

MTN 005 Laboratory Training. Lorna Rabe MTN Network Laboratory Magee-Womens Research Institute Pittsburgh, PA

Section 10. Counseling Procedures

Demographics. 2. What was your sex at birth? If female, participant is ineligible. End of form.

9.1 Overview and General Guidance This section contains information on the laboratory procedures performed in MTN-035.

Section 8. Clinical Considerations

Specimen Management PHRU LAB

VOICE (MTN-003) IT S ALL ABOUT THE ENDPOINTS. Edward Livant MT (ASCP), MPH University of Pittsburgh Medical Center MTN Network Laboratory

MTN-038 SSP Manual Version November 2018 Section 10 Page 10-1 of 10-30

QA Processes That Work: Minimizing Errors During On-site Rapid HIV Testing

Section 10 Counseling Considerations

Goal of site data management 12/2/2009. Ultimate goal: reliable and valid clinical trial to improve health

The Feasibility of HIV Prevention Cohort Studies among Men who have Sex with Men (MSM) in sub-saharan Africa

GSK , 2.0, 18, 2014, DAIDS

MTN-026 Clinical Management Overview

Section 9. Laboratory Considerations

WOMEN'S INTERAGENCY HIV STUDY

Clinical Considerations. Review

Section 9 Laboratory Consideration

An Update on FACTS 001. Prof Helen Rees FACTS Protocol Chair

HPTN 035. Laboratory Overview

SUMMARY OF CHANGES INCLUDED IN THE FULL PROTOCOL AMENDMENT OF: MTN-004 DAIDS Document ID 10492

Quicker, Better, Faster Optimising Turn Around Time of Laboratory Results

SUMMARY OF CHANGES INCLUDED IN THE FULL PROTOCOL AMENDMENT OF: MTN-014. DAIDS Protocol #:11885

Cleveland Prevention Update. Zach Reau HIV Prevention Program Manager Ohio Department of Health

PrEP Home Checklist v1.0

Non-Occupational Post-Exposure HIV Prophylaxis npep

The laboratory preparation for a new study a pragmatic approach. Compiled by Ken Clarke and Lindiwe Nhlangulela October 2011

MedDRA Coding/ AE Log Item 1 Refresher. ASPIRE Protocol Team Meeting February 10, 2013

Getting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day

Control Efforts for Trichomoniasis in STD Clinics

Removing Unnecessary Barriers to Contraceptive Services

If the HPTN 082 protocol is amended in the future, this Letter of Amendment will be incorporated into the next version.

CLINICAL MANAGEMENT OF STDS

Research Compliance and Quality Assurance Program (RCQA): Audit Checklist Subject Specific

MTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012

FOR CALENDAR YEAR 2014 DATA

Letter of Amendment # 3 to:

Percentage of family planning clinics, according to clinic characteristics, by service focus, Title X funding status and clinic type, 2010 and 2015

Chronic Pelvic Pain Case Study

Action Item for 2019 Review of Tool. Maintain (add include oral cavity) Maintain. Archive. Archive. 12 creatinine)

SFAF CLINICAL PROTOCOLS

FHI Study 10015: FEM-PrEP

Section 9. Laboratory Considerations

ONLINE SUPPLEMENTARY MATERIALS: FILE 1

Julie Nelson RNC/WHNP-BC Epidemiology NURS 6313

Updated Guidelines for Post-Assault Testing and Treatment

ACHA Pap Test and STI Data Survey. Calendar Year 2009

November 9, Clarification Memo 1 Version 3.0 HVTN 704/HPTN 085

Overview of Wet Preps and Gram stains. Lorna Rabe Central Lab Magee-Womens Research Institute Pittsburgh, Pa

Contraception. Yolanda Evans MD MPH Assistant Professor of Pediatrics Division of Adolescent Medicine

Sexually Transmitted Infections in HSV-2 Seropositive women in Sub- Saharan Africa HPTN 039

The HIV Prevention Product Pipeline for Adolescents JANUARY 8 TH, 2018

Preventive Services Explained

Clinical Services Guideline

ADOPTED REGULATION OF THE STATE BOARD OF HEALTH. LCB File No. R Effective December 3, 2003

Prior to site activation the following events were lined up

PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program

CONTINUED LESSONS FROM VOICE

Section 13. Laboratory Considerations

2018 Preventive Schedule

Informed Consent Flipchart. Version 1.0, 30 Jan 2018

The Promise of HIV Prevention in Pregnancy. Richard H. Beigi, MD., MSc. University of Pittsburgh Pittsburgh, PA USA

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?

MYCOPLASMA GENITALIUM A PRACTICAL GUIDE

Target Product Profiles for Drug-Drug and Drug-Device MPT Products

Population attributable fraction of genital inflammation and ulceration in HIV risk among discordant couples, Zambia,

LONG-ACTING REVERSIBLE CONTRACEPTION. Summary Tables

PrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute

MTN 034/IPM 045: REACH Rings and PrEP in Young Women

Pre-exposure Prophylaxis for HIV Prevention

Answers to those burning questions -

Family Planning Eligibility Program

MTN-020 and IPM 027 and the MTN-020 DSMB. Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012

Committee on Methodological Challenges in HIV Prevention Trials. Institute of Medicine Stephanie Skoler, MPH February 6, 2007

TO DECREASE THE CHANCE OF GETTING

Medicaid Family Planning Waiver Services CPT Codes and ICD-10 Diagnosis Codes

Management of NGU (Non-gonococcal urethritis)

2018 Preventive Schedule

The Kisumu Clinical Research Site. Mumbi Makanga MBChB, MPH MTN Regional Meeting 28 th September 2016

SINDAWONYE Clinical Trials Unit

Navigating Alliance Protocols

Section 10. Laboratory Considerations

Remind me, what s an STI? And why are they relevant to me?

Section 9. Laboratory Considerations

Transcription:

SCREENING AND ENROLLMENT CONSIDERATIONS MTN-038 STUDY-SPECIFIC TRAINING

SCREENING AND ENROLLMENT VISITS Screening/ Visit 1 Eligibility Criteria initially assessed Multiple visits, if needed (Split visit) One re-screen attempt permitted Enrollment/Visit 2 Day 0 Eligibility Criteria Confirmed No split visit permitted Start study product use Long visit for PK collection 45 day window *not to coincide with participant s menses

ADMINISTRATIVE PROCEDURES Screening Visit Procedure Enrollment Visit Initial collection per site SOP Conduct process: read, assess, confirm, document Initial assignment: Complete S&E Log; PTID Name Linkage Log Collect via Demographic CRF Initial assessment: Age, co-enrollment, Screening Behavioral Eligibility N/A Locator Information collection Informed Consent PTID assignment Demographic Information Eligibility Assessment Study Arm Randomization Review/update per site SOP Review/ reconfirm Use same PTID; Update S&E Log N/A Confirmation: Co-enrollment, Enrollment Behavioral Eligibility Via Medidata; after final eligibility sign-off For Enrollment; within 45-days Next Visit Schedule Visit 3/ Day 1 (next day) Per site SOP Reimbursement Provision Per Site SOP

Informed Consent Complete 1 st part of coversheet Read ICF Assess Comprehension Complete 2 nd part of Coversheet

Screening and Enrollment Log Only complete if ppt provides IC Completed immediately after IC completion at Screening and updated after eligibility determination at Enrollment One entry for each screening attempt (note if 1 st or 2 nd screening attempt) Fill out all codes that apply

Screening and Enrollment Behavioral Eligibility Screening Behavioral Eligibility Worksheet Enrollment Behavioral Eligibility Worksheet

COUNSELING AND BEHAVIORAL PROCEDURES Screening Visit Procedure Enrollment Visit HIV Pre-Test STI Risk Reduction HIV Post-Test Behavioral Assessment HIV/STI Counseling Baseline CASI (before HIV and pregnancy testing); Select for IDI (after study arm randomization) HIV Pre-Test STI Risk Reduction HIV Post-Test Contraceptive Component only Protocol Adherence Counseling Protocol Adherence, Contraceptive, and Product Use components Offer, if indicated Male Condoms Offer, if indicated

Counseling Considerations HIV Pre- and Post-Test and STI Risk Reduction Counseling Prior to HIV testing: provide HIV pre-test and STI risk reduction Counseling Refer to SSP Table 11-1 for HIV Test interpretation guidance If HIV test results will not be available during the visit, post-test counseling may occur upon provision of test results over the phone or in person as part of a split visit or at an interim visit, if indicated per local standard of care. Document on Counseling Worksheet or in chart notes. Initial and date each entry.

Counseling Considerations Protocol Counseling Worksheet: Protocol Adherence, Product Use, and Contraceptive Counseling

Counseling Considerations Protocol Adherence Support documents: Study Adherence Guidelines VR Use Instructions

CLINICAL/ PRODUCT PROCEDURES Screening Visit Procedure Enrollment Visit Collect baseline medical/ menstrual/ Medications Hx Medical History Review Review/update baseline medical/ menstrual/ medications Hx Full Physical Exam Targeted Full exam Pelvic Exam Full Exam Lab and exam findings for initial eligibility If indicated Per site SOP (at visit or when available) N/A Review findings Referrals/Rx for UTIs/RTIs/STIs Provision of Available Results Study Product Lab and exam findings for eligibility confirmation If indicated Per site SOP (at visit or when available) Initial VR provision, digital placement check

Baseline Medical History Review Baseline Medical History Guide Use guide for assessing baseline medical and menstrual history; document on: Chart Notes Medical History Concomitant Medications Log Document dates of LMP in Chart notes or Visit Checklists

LABORATORY ASSESSMENTS Screening Visit Procedure Enrollment Visit HIV 1/2 AST/ALT Creatinine clearance CBC with differentials/ platelets Hep B surface antigen Syphilis serology Blood HIV 1/2 Plasma for archive HSV 1/2 serology CBC with differentials/ platelets* Creatinine clearance* Pregnancy Dipstick UA, Urine Culture* NAAT for GC/CT and trichomonas Pap Test^ Wet prep/koh wet mounts* Urine Pelvic Pregnancy Dipstick UA, Urine Culture* Vaginal swabs for microbiota Vaginal gram stain CVF for anti-hsv-2 and biomarkers CVL for PD and biomarkers (prior to insertion) CVF for TFV(1 & 4 hrs-post ring insertion) Wet prep/koh wet mounts* NAAT for GC/CT and trichomonas*

ELIGIBILITY DETERMINATION Eligibility Criteria Checklist Guide for inclusion/exclusion criteria and source documentation Start at Enrollment Visit and complete only if participant is eligible. Required before enrollment for eligible participants (2 sign-off signatures) At any point the participant is deemed ineligible at Enrollment, no need to continue completing

REQUIRED DOCUMENTATION FOR SCREEN FAILURES Completed ICF All source documentation complete up until the time that ineligibility was determined indicating what procedures were or were not completed and/or screen failure reasons and date of ineligibility determination noted. Visit Checklist Chart notes Completed Screening and Enrollment Log Completed Inclusion/Exclusion Criteria CRF with screen failure reason(s) noted Necessary referrals on file (as appropriate) and documentation that any clinically significant abnormalities (labs, etc.) were communicated to the participant (even if referral is not necessary)

PARTICIPANT ENROLLMENT Confirm and document eligibility Randomization to study arm Complete Post- Randomization Procedures Post-Randomization Procedures IDI randomization/selection VR Request/Retrieval from pharmacy Ring insertion and placement check Specimen collection for TFV level testing (CVF only) Schedule visit for next day(generate visit calendar) Provide reimbursement, study staff contact information, etc. Update Screening and Enrollment Log

QUESTIONS? COMMENTS?